CLYM Stock Summary and Trading Ideas (Climb Bio | NASDAQ:CLYM)

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Climb Bio trades on the NASDAQ stock market under the symbol CLYM.

As of March 30, 2026, CLYM stock price declined to $6.54 with 291,872 million shares trading.

CLYM has a beta of 1.47, meaning it tends to be more sensitive to market movements. CLYM has a correlation of 0.06 to the broad based SPY ETF.

CLYM has a market cap of $312.25 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that CLYM belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.

CLYM has outperformed the market in the last year with a return of +410.9%, while the SPY ETF gained +15.1%. In the last 3 month period, CLYM beat the market returning +62.3%, while SPY returned -7.7%. However, in the most recent 2 weeks CLYM has underperformed the stock market by returning -8.3%, while SPY returned -5.3%.

CLYM support price is $6.60 and resistance is $7.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLYM shares will trade within this expected range on the day.